Yesterday, February 19, 2013, we published a brief introductory article detailing several reasons why we believed Green Innovations (GNIN.OB) was a train wreck waiting to happen. After hitting a high of $3.35 in early trading the stock ended yesterday’s trading […]
As promised, here are some initial details regarding what we have been able to uncover on Green Innovations (OTCBB:GNIN), to be elaborated on in another installment. GNIN Is a Train Wreck Waiting To Happen The second that we came upon […]
China Central Television Coverage of Longwei Petroleum Reinforces GeoInvesting’s Findings of Fraud
On Monday, January 28, 2013, China Central Television Channel One (CCTV-1), the largest national Chinese government-run news network, aired a special investigative report titled “Investigation of the Truth Behind Longwei Petrochemical” verifying our findings on the Longwei Petroleum (LPH) fraud. […]
GeoNuggets® – Quick Check List Highlighting Undiscovered Opportunities On 12/03/2012, we coded Mastech Holdings (MHH) as a GeoBargain on the radar @ $5.15 (Adjusted for $2.00 special dividend). On 12/19/2012 we coded MHH as a GeoBargain @ $5.50 (Adjusted for $2.00 […]
Simply put, Mer Telemanagement (NASDAQ:MTSL) sells call accounting software and tools to help its end users manage internal communication activities as well as external billing and invoice needs. At first glance, MTSL’s history did not leave us overly excited to […]
Our preliminary due diligence on Nautilus Group (NLS) led us to code the company as a GeoBargain at $3.70 on January 2, 2013. Astute investors who are on the prowl for undervalued stocks can often find value in companies that […]
Longwei Petroleum (LPH) published two 10-minute video clips today in an effort to refute our video evidence of little or no activity at LPH’s Taiyuan plant. It has been eight days now since we first released our report and this […]
Navidea Biopharmaceuticals (NAVB) is one of the most attractive short opportunities we have seen in some time. The company resubmitted its long-awaited drug candidate, Lymphoseek, to the FDA on October 31, 2012. Any “emotional” pop in NAVB’s share price that […]